Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Genes for prostate cancer mapped for the first time

A genetic blue print that uncovers many of the mutations and genetic damage that drives prostate cancer and could lead to new treatments and better diagnosis has been found. This would mean earlier detection and new breeds of drugs to reverse the damage. Also each patient could have his own “cancer chart” made so that his treatment is personalized. The study, conducted by researchers from the Broad Institute, Dana-Farber Cancer Institute and Weill Cornell Medical College, appears in the Feb. 10 issue of Nature.

13 Feb 2011

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer. Tesetaxel, the leading oral taxane in clinical development, will be evaluated for its use as both first- and second-line chemotherapy.

10 Feb 2011

Full genetic blueprint of multiple prostate tumors laid bare

For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. The study, made possible by key advances in whole genome sequencing and analysis, points to several new prostate cancer genes and a critical category of genomic changes as important drivers of prostate cancer growth.

10 Feb 2011

Myriad Genetics' 46-gene PROLARIS molecular diagnostic test predicts prostate cancer outcome

Myriad Genetics, Inc. announced today that a study published in Lancet Oncology shows the Company's 46-gene PROLARIS™ molecular diagnostic test significantly predicts prostate cancer outcome.

10 Feb 2011

Everolimus phase III study shows improved progression-free survival in patients with pNET

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Feb 2011

PBNC technology may help detect cardiac disease, reduce diagnostic costs

Heart disease is a silent killer, but new microchip technology from Rice University is expected to advance the art of diagnosis.

9 Feb 2011

Men with high levels of CCP genes more likely to have fatal form of prostate cancer

A genetic pattern could predict how aggressive prostate cancer is before treatment, and whether the disease will come back in men who have already been treated, according to research published1 in the Lancet Oncology.

9 Feb 2011

Study finds dutasteride not cost-effective in prevention of prostate cancer in men at elevated risk

The popular drug dutasteride may not be a cost-effective way to prevent prostate cancer in men who are at elevated risk of developing the disease, according to findings by a UT Southwestern Medical Center researcher.

9 Feb 2011

CytRx's bafetinib helps reduce skeletal complications in cancer patients

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies show that bafetinib may be useful in preventing bone loss in cancer patients who are at high risk for this event.

8 Feb 2011

Study shows dogs can be trained to detect PCa by smelling urine

In the February 2011 issue of European Urology, Jean-Nicolas Cornu and colleagues reported the evaluation of the efficacy of prostate cancer detection by trained dogs on human urine samples.

8 Feb 2011

Executive wellness a legit corporate expense

At least once a year, executives from Ciena Corp. spend a day at Johns Hopkins University getting poked and prodded as they undergo tests for a barrage of potential ailments, from anemia to prostate cancer. They

8 Feb 2011

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

7 Feb 2011

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that they have entered into an exclusive worldwide (except Japan) agreement by which Salix has licensed rights to RELISTOR® (methylnaltrexone bromide).

7 Feb 2011

British Journal of Dermatology publishes data on DermTech's new genomic assay for melanoma

DermTech International, a biotechnology company dedicated to bringing genomic medicine to dermatologists, today announced that the discovery data on its new genomic assay for melanoma have been published in the British Journal of Dermatology.

7 Feb 2011

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.

4 Feb 2011

Metamark announces Nature journal published landmark prostate cancer study results

Metamark Genetics, Inc., a privately-held oncology molecular diagnostics company, today announced results from a landmark prostate cancer study published as an Advance Online Publication in the journal Nature.

3 Feb 2011

Four-gene/protein signature more accurately predicts metastatic prostate cancer

Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers at Dana-Farber Cancer Institute report in a study published online today by the journal Nature. The discovery lays the groundwork for the first gene-based test for determining whether a man's prostate cancer is likely to remain dormant within the prostate gland, or spread lethally to other parts of the body.

3 Feb 2011

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon DNA vaccine for prostate cancer targeting two antigens.

2 Feb 2011

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Harbor BioSciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced publication of newly discovered anti-inflammatory steroids naturally present in humans.

2 Feb 2011

Trained dog sniffs out colon cancer with 98% accuracy

For the study the researchers at Kyushu University trained an 8-year-old female Labrador retriever named Marine who was given breath and stool samples of 306 patients, collected right before they received colonoscopies.

2 Feb 2011

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Genes for prostate cancer mapped for the first time

Genta initiates new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer

Full genetic blueprint of multiple prostate tumors laid bare

Myriad Genetics' 46-gene PROLARIS molecular diagnostic test predicts prostate cancer outcome

Everolimus phase III study shows improved progression-free survival in patients with pNET

PBNC technology may help detect cardiac disease, reduce diagnostic costs

Men with high levels of CCP genes more likely to have fatal form of prostate cancer

Study finds dutasteride not cost-effective in prevention of prostate cancer in men at elevated risk

CytRx's bafetinib helps reduce skeletal complications in cancer patients

Study shows dogs can be trained to detect PCa by smelling urine

Executive wellness a legit corporate expense

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

British Journal of Dermatology publishes data on DermTech's new genomic assay for melanoma

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Metamark announces Nature journal published landmark prostate cancer study results

Four-gene/protein signature more accurately predicts metastatic prostate cancer

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Trained dog sniffs out colon cancer with 98% accuracy

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in